The U.S. Food and Drug Administration has approved Galderma's Nemluvio (nemolizumab) for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older.
But this year the injection was at risk of being pulled from the PBS by the supplier, leaving patients to fork out $20,000 for a prescription - instead of $32 - or go without. "From the first of ...
Eczema can occur anywhere on the body, but it is common on the backs of the knees. This is due to areas of skin rubbing against each other and moisture forming in the skin creases. Eczema refers ...